ABBV ▲ +0.5% - AbbVie Inc. $ABBV - U.S. FDA Approves Subcutaneous Induction Regimen for AbbVie's SKYRIZI® (risankizumab-rzaa) for Adults With Moderately to Severely Active Crohn's Disease 23-OCT-2026 03:34 PM ET